Reported results
- Total net revenues for the quarter were $193.4 million.
- Gross margin for the quarter was 77%.
- Net loss for the quarter was $10.4 million.
- Adjusted EBITDA for the quarter was $15.7 million.
- As of September 30, 2026, there were 5,260 total active patients on TTFields therapy globally.
Guidance
- Full-year 2026 total net revenue: $736 million - $743 million
- Full-year 2026 Adjusted EBITDA: $24 million - $34 million
Price and volatility reaction
The stock moved -7.5% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -26.4 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 14.17 | 2026-10-28 |
| Close after release | 13.11 | 2026-10-29 |
| Realised move | -7.5% | close to close |
| 30d ATM IV change | -26.4 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-29 (8-K, Item 2.02). Read the original filing on sec.gov.
